Johnson & Johnson (JNJ) reported Q4 FY2022 earnings of $2.35 per share (versus $2.13 per share in Q4 FY2021), beating analysts’ consensus estimate of $2.24 per share.
The company’s quarterly revenues amounted to $23.706 bln (-4.40% y/y), roughly in line with analysts’ consensus estimate of $23.901 bln.
JNJ rose to $171.00 (+1.60%) in pre-market trading.
